Dr. Grosso

Dolores Grosso, DNP, CRNP

Contact Dr. Grosso

834 Chestnut Street
Suite 320
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome
  2. Relapsed Multiple Myeloma Presenting as Intracranial Plasmacytoma and Malignant Pericardial Effusion following Recent Allogeneic Stem Cell Transplantation
  3. Acquired uniparental disomy in chromosome 6p as a feature of relapse after T-cell replete haploidentical hematopoietic stem cell transplantation using cyclophosphamide tolerization
  4. Evaluating frequency and quality of pathogen-specific T cells
  5. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation
  6. A two-step approach to myeloablative haploidentical transplantation: Low nonrelapse mortality and high survival confirmed in patients with earlier stage disease
  7. Posttreatment interleukin-2 in patients with acute myeloid leukemia: The end of a long road for patients and clinical trials?
  8. Recent advances in haploidentical stem cell transplantation
  9. A two-step approach to allogeneic haploidentical hematopoietic stem cell transplantation
  10. Double Haploidentical Hematopoietic Stem Cell Transplantation Results in Successful Engraftment of Bone Marrow from Both Donors without Graft-versus-Host or Graft-versus-Graft Effects
  11. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing
  12. Antiviral Responses following L-Leucyl-L-Leucine Methyl Esther (LLME)-Treated Lymphocyte Infusions: Graft-versus-Infection without Graft-versus-Host Disease
  13. Gefitinib in patients with progressive high-grade gliomas: A multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
  14. Treatment of Adenovirus Disease in Stem Cell Transplant Recipients with Cidofovir
  15. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial
  16. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: A phase I study
  17. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma
  18. Cytoprotection in acute myelogenous leukemia (AML) therapy
  19. Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches
  20. High complete remission rate and normal organ cytoprotection using dose escalation of idarubicin with amifostine in high risk patients with AML